To assess the cost-effectiveness of routine Lynch syndrome (LS) screening among colorectal cancer (CRC) patients ≤70 years of age.
INTRODUCTION
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, responsible for 2-3% of all CRC cases. [1] [2] [3] This syndrome is characterized by early onset of CRC, endometrial cancer, and other extracolonic cancers. 4 Mutations in one of the four mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 or the TACSTD1 gene are the underlying defect in LS. 5 Detection of LS in CRC patients is of great importance because affected patients and family members can benefit from LS surveillance programs, which reduce CRC incidence and mortality by 56-70%. 6, 7 Molecular diagnostics on tumor tissue consisting of analysis for microsatellite instability (MSI) and immunohistochemical staining (IHC) for loss of MMR protein expression can identify patients at high risk for LS. 8, 9 However, loss of MLH1 protein expression can also occur in sporadic tumors as a result of somatic MLH1 promoter hypermethylation. Therefore, sporadic MLH1-deficient tumors can be distinguished from LS-associated tumors by MLH1 hypermethylation analysis. 9 The revised Bethesda guidelines have been developed to select patients eligible for MSI testing and IHC analysis based on clinical criteria. 10 These guidelines are poorly applied in clinical practice and may miss a substantial number of LS patients because of limited sensitivity. 11 Routine analysis of MSI and IHC was previously recommended in CRC patients <50 years of age. 12 This strategy predominantly fails to identify MSH6 and PMS2 mutation carriers because the mean age of CRC diagnosis in these subjects is >50 years. 13, 14 Routine screening for LS has been proposed to improve LS detection, but age cutoffs are still under debate. [15] [16] [17] Recently, the US Multi-Society Task Force on Colorectal Cancer as well as a European group of experts recommended routine LS screening via analysis of MSI Submitted Original research article or IHC and MLH1 hypermethylation in CRC patients. 18, 19 The US guidelines support universal tumor testing for LS, whereas European experts recently recommended universal LS screening or routine screening of CRC patients up to 70 years of age.
We previously reported that routine analysis of MSI and IHC for MMR proteins revealed a profile compatible with LS in 4.5% of CRC patients ≤70 years of age. 20 Many of these patients were >50 years of age. 20 The current study aimed to assess the cost-effectiveness of routine screening for LS by analysis of MSI, IHC, and MLH1 hypermethylation in CRC patients ≤70 years of age. We compared costs and health benefits for age-targeted LS screening up to 70 years of age. Also, we compared routine LS screening among CRC patients up to age 70 with LS screening based on the revised Bethesda guidelines.
MATeRIALs AND MeTHODs subjects and diagnostic workup
The present study is an extension of a prospective populationbased study on the yield of routine molecular screening for LS in CRC patients up to 70 years of age. 20 Consecutive CRC patients ≤70 years of age (n = 1,117) from 11 Dutch hospitals between May 2007 and September 2009 were included. The diagnostic approach and methods regarding tumor analyses and germ-line mutation analyses have been described in detail elsewhere. 20 In summary, MSI analysis and IHC for MLH1, MSH2, MSH6, and PMS2 protein expression were performed in tumor tissue of CRC patients ≤70 years of age. MLH1 hypermethylation analysis was performed in cases with loss of MLH1 protein expression. BRAF mutation analysis was not included in this cost study because previous studies have shown that MLH1 promoter hypermethylation analysis is superior to BRAF mutation analysis as a prescreening method. 21 If tumors showed a high degree of MSI and/or absence of MMR protein without MLH1 promoter hypermethylation, then patients were suspected of having LS. These patients were offered genetic counseling and germ-line mutation analysis (Figure 1) . If patients suspected of having LS had died before they could be referred to a clinical geneticist, then genetic counseling was offered to their first-degree relatives. In the Netherlands, costs of genetic counseling and germ-line mutation analysis are covered by the mandatory basic health insurance.
If a pathogenic germ-line mutation was identified in one of the MMR genes or the TACSTD1 gene, then patients were labeled index patients. Relatives were contacted by index patients and were offered genetic counseling and targeted mutation analysis. We collected data on the number of relatives accepting counseling and targeted mutation analysis and the number of LS carriers identified among these relatives until May 2014. This study was approved by the institutional review boards of the participating hospitals.
effectiveness
Effectiveness of LS screening was expressed in life years gained (LYG), based on the number of LS carriers detected among CRC patients and their relatives and using estimations from literature. In previous studies, LS surveillance was associated with 0.09-2.5 LYG for index patients and 0.49-32.69 LYG for relatives. 12, 16, 17, [22] [23] [24] [25] [26] [27] [28] [29] For our analysis, we took the reported 3% discounted LYG directly from previous studies. If only undiscounted LYG or LYG with a different discount rate was reported, then we discounted them by 3% annually (Supplementary Table S1 online). If adherence to LS surveillance programs was not included in the reported LYG, then we corrected the LYG by assuming adherence to these programs of 80% for both index patients and LS carriers among their relatives. 16 We used the median of all estimations from the literature in our base case scenario ( Table 1) . If the index patient had died, then only relatives were considered to benefit from surveillance. For CRC patients and relatives with no pathogenic mutation identified, we assumed no surveillance costs or benefits.
Costs
Direct medical costs of all analyses in the diagnostic workup were determined following the microcosting method, which is based on comprehensive bottom-up analyses. 30 Cost data included costs of employment, material, equipment, and overhead, which were obtained from the Department of Pathology and the Department of Clinical Genetics of the Erasmus MC, University Medical Center Rotterdam (Supplementary Table S2 online). Costs of PMS2 germ-line mutation analysis were assumed to be similar to costs of germ-line mutation analysis of other MMR genes. Total costs were calculated based on the number of CRC patients and relatives analyzed. The costs of MMR gene sequencing in index patients were calculated using the total number of genes analyzed. LS surveillance costs for index patients and relatives were estimated from previous literature, including costs of colonoscopy, transvaginal ultrasonography, and endometrial biopsy ( Table 1 and Supplementary Table S2  online) . 16, 31 Costs of gynecological screening were available only in dollars and were converted to Euros using purchasing-power parity. All costs were converted to the price level of 2013 using the Dutch consumer price index. 32 Surveillance by colonoscopy with polypectomy every 2 years was assumed to start at the age of LS diagnosis or at age 25 for relatives younger than 25 years of age. LS surveillance was assumed to be continued until 75 years of age. For cost savings by prevention of CRC in surveillance programs, the most conservative estimate, i.e., only treatment costs for the first 12 months of stage I CRC, was used (Supplementary Table S2 online). Female LS carriers were assumed to receive yearly gynecological surveillance by transvaginal ultrasonography and endometrial biopsy starting at age 35 and continuing until prophylactic surgery at 40 years of age, after childbearing was completed. Prophylactic surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy) was assumed to be accepted by 19% of the index patients and 18% of their relatives. 16 LS carriers not accepting prophylactic surgery were assumed to continue yearly gynecological surveillance up to 75 years of age. All costs were discounted by 3% annually.
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Cost-effectiveness analyses
We evaluated cost-effectiveness of LS screening using a base-case cost-effectiveness model (i.e., using the most plausible parameter values), and age cutoffs of 60 and 70 years from a health-care-provider perspective. LS screening was the reference strategy for CRC patients ≤50 years of age. Incremental cost-effectiveness ratios (ICERs) per age cutoff were expressed as additional costs per LYG. To test the robustness of ICERs, we performed one-way sensitivity analyses. Costs were assumed to range from half as much to twice as much as calculated. Ranges for all other parameters were based on literature ( Table 1) .
Fulfillment of the revised Bethesda guidelines
The proportion of CRC patients fulfilling the revised Bethesda guidelines was based on the literature ( Table 1) . In an unselected population, 26-50% of CRC patients fulfill the revised Bethesda guidelines. 1, 3, 33 We assumed only 26% of the CRC patients in our cohort fulfilled these guidelines, because this approach is unfavorable for an age-targeted screening strategy. For all index patients, a detailed family history was obtained during genetic counseling and fulfillment of the revised Bethesda guidelines was assessed by one clinical geneticist (A.W.).
ResULTs
In our population-based cohort, 50 of 1,117 CRC patients (4.5%) were suspected of having LS by routine analysis of MSI and IHC (Figure 1) . Consecutive MMR gene sequencing in 42 of these CRC patients finally identified 24 LS patients (2.1%). In one case, the germ-line mutation was identified in stromal tissue resected along with the CRC tissue. Because neither this patient nor any relatives were available for MMR gene sequencing, the patient was not considered an index patient.
effectiveness of age-targeted strategies
The median age of CRC patients was 61 years (interquartile range: 55-66); 144 CRC patients were ≤50 years of age, 377 CRC patients were 51-60 years, and 596 CRC patients were 61-70 years. The prevalence of LS decreased from 4.9% (7/144) in the age category ≤50 years to 2.1% (8/377) in CRC patients 51-60 years and 1.5% (9/596) in CRC patients 61-70 years ( Table 2) .
For index patients ≤50 years of age, a total of 29 first-degree relatives were eligible for targeted mutation analysis compared with 44 and 40 first-degree relatives in the age categories 51-60 years and 61-70 years, respectively. Genetic counseling and targeted mutation analysis were offered to these relatives and cascaded to further relatives if indicated. For each index, † In 4 of 41 cases, germ-line mutation analysis was performed in a first-degree relative.
‡ In one patient, a pathogenic MMR mutation was identified in stromal tissue resected during colorectal cancer surgery. Neither this patient nor any relatives were available for germ-line mutation analysis. This patient was excluded from the analyses. In one additional case, a germ-line mutation was identified in stromal tissue resected along with the CRC tissue. This patient was not considered an index patient because the patient and none of the relatives of that patient were available for germ-line mutation analysis. patient a median of 3 (interquartile range: 2-8) relatives finally accepted counseling and germ-line targeted mutation analysis. A wide range-from 1 to 37 relatives-was tested for LS. In total, targeted mutation analysis was accepted by 140 relatives, identifying 70 additional LS carriers. Notably, more than three times as many LS carriers were identified among relatives of CRC patients 51-60 years of age as in the other age categories ( Table 2) . This difference was partly attributable to one index patient in the 51-60 age category with 37 relatives tested and 16 LS carriers identified.
Based on a median estimated benefit of LS surveillance of 0.66 years per index patient and 2.83 years per relative, a total of 205.9 life years were estimated to be gained by LS screening in CRC patients ≤70 years of age. Surveillance of relatives led to the highest benefit, with a total of 192.7 LYG compared with a total of 13.2 LYG for index patients.
Costs and cost-effectiveness
Total costs of LS molecular screening and subsequent surveillance increased from €229.166 (€10.931 per LS carrier detected) for CRC patients ≤50 years of age to €1.040.005 (€11.183 per LS carrier detected) for CRC patients ≤70 years of age (Figure 2) .
LS screening for CRC patients ≤60 years of age had an ICER of €4.226/LYG compared with screening patients ≤50 years of age. The ICER of LS screening in CRC patients ≤70 years of age compared with screening CRC patients ≤60 years of age was €7.051 per LYG ( Table 3) .
In one-way sensitivity analysis, the ICERs were most sensitive to the assumed LYG by relatives (Supplementary Figure S1 online). The ICER for screening CRC patients ≤60 years of age compared with screening patients with CRC diagnosed at ≤50 years of age never exceeded €8.000/LYG. After exclusion of all family members of the largest family in our cohort (37 relatives, 16 LS carriers), this ICER remained less than €10.000/LYG. The ICER for screening CRC patients ≤70 years of age compared with screening CRC patients ≤60 years of age remained less than €13.000/LYG under all assumptions (Supplementary Figure S1 online) .
Fulfillment of the revised Bethesda guidelines
In our cohort, the revised Bethesda guidelines would have identified 17 of 23 (74%) index patients and 53 of 70 (76%) 
DIsCUssION
Our economic evaluation indicates that routine screening for LS in CRC patients ≤70 years of age by analysis of MSI, IHC, and MLH1 hypermethylation is cost-effective according to currently accepted standards. In a one-way sensitivity analysis, expanding routine screening for LS from CRC patients ≤50 years of age to CRC patients ≤60 years of age never exceeded €10.000/LYG. Costs of LS screening among CRC patients 61-70 years of age were €7.051/LYG in our base case analysis and remained less than €13.000/LYG in one-way sensitivity analysis. The cost-effectiveness threshold of any diagnostic strategy depends on a health-care system's willingness to pay for each LYG. In the Dutch health-care system, willingness to pay depends on severity of the disease, and most interventions will be considered cost-effective if costs remain less than €40.000/LYG. 34 In the United Kingdom and the United States, a threshold of $50,000/LYG (~€40,000/LYG) is commonly used in cost-effectiveness analyses for cancer screening. However, thresholds over $50,000/LYG can also be justified. 35 Our sensitivity analysis confirmed the finding of other studies that the assumed benefit (LYG) from LS surveillance has a tremendous effect on ICERs, especially LYG assumed for relatives. 12, 16, 17, 23, 24, 27 The benefit of LS surveillance programs for relatives that we estimated from literature ranged from 0.40 LYG to 16.74 LYG per relative ( Table 1 and Supplementary Table  S1 online). These extreme differences reflect the impact of assumptions made on uncertain parameters such as CRC risk for LS carriers, the method and risk reduction of LS surveillance, and assumed adherence to LS surveillance programs. In our base case analysis, we used the median of all estimations from the literature to attain plausible estimates. In our one-way sensitivity analyses, we considered the full range of estimates from the literature, which resulted in ICERs well within currently accepted thresholds for cost-effectiveness. Specifically, all ICERs remained less than €13.000/LYG. LS screening in CRC patients ≤70 years of age identified more than three times as many LS index patients compared with screening only CRC patients ≤50 years of age. Also, LS carriers among family members of these index patients were identified. We found a median of three relatives who were tested for each index patient. However, there was a very wide range-from 1 to 37-of relatives who were tested per index patient for a total of 140 relatives. Interestingly, in our study more than three times as many LS carriers were identified among relatives of CRC patients 51-60 years of age compared with the other age categories. This difference was partly caused by a very large family with 37 relatives tested and 16 LS carriers identified, which we may consider as a statistical outlier. Furthermore, the 51-60 age group contained 1.5 times as many first-degree relatives eligible for genetic testing compared with index patients ≤50 years of age and had a higher prevalence of LS among tested relatives compared with the 61-70 years age category. Older age of siblings for CRC patients in the 61-70 years age category compared with siblings of younger CRC patients might explain this difference in LS prevalence because of the reduced life expectancy of LS carriers. Our study may still underestimate the number of LS patients ultimately detected among relatives. Relatives who do not undergo targeted mutation analysis as well as minors not yet eligible for genetic testing could request genetic testing at a later time. Also, CRC patients suspected of having LS who declined genetic testing might opt for MMR gene sequencing in the future, thereby further increasing the identification of LS carriers among CRC patients and their relatives. Further studies of these issues are necessary.
Our results are in line with previous studies using decision-analytic models, in which LS screening by only IHC testing or analysis for MSI for CRC patients >50 years of age was found to be cost-effective. 16, 17, 26, 27 In one study LS screening of CRC patients ≤60 years of age led to an ICER of $33,800/LYG (€25,000/LYG) compared with screening patients ≤50 years of age. Expanding the age limit for LS screening to CRC patients ≤70 years of age resulted in an ICER of $44,200/LYG (€33,000/ LYG). 16 By contrast, a recent Dutch study found an ICER of only €2,703 for LS screening in CRC patients ≤70 years of age compared with LS screening of CRC patients ≤50 years of age. 26 However, this study did not include costs of gynecological surveillance. Furthermore, LYG for relatives in their study was 6.9 to 7.22 years, which is higher than assumed in other studies of cost-effectiveness of LS screening. Interestingly, the assumed incidence of CRC in LS carriers was higher than in other studies, which accounts for their high estimate of LYG per relative tested compared with other recent studies on cost-effectiveness of LS screening. Because we used the median of all estimates for LS benefit from the current literature, our ICERs are between those found by Sie et al. and those found by recent studies assuming benefit for LS carriers among relatives with less than 1 LYG.
Sensitivity of the revised Bethesda guidelines was 74% in our cohort. In previous literature, the sensitivity of these guidelines was 72-88%. 19 To assess cost-effectiveness of age-targeted LS screening compared with the revised Bethesda guidelines, we assumed that only 26% of CRC patients in our cohort fulfilled the revised Bethesda guidelines. We assumed 100% adherence to the revised Bethesda guidelines, whereas in clinical practice molecular diagnostics for LS may be performed in only 11-14% of the patients fulfilling these guidelines. 11, 36 In a previous study, low rates of failure to apply the revised Bethesda guidelines made LS screening by molecular diagnostics the preferred strategy. 16 In our study, the ICER for LS screening among CRC patients ≤70 years of age compared with testing according to the revised Bethesda guidelines remained less than €13.000/ LYG. Age-targeted LS screening may be much easier and therefore even more cost-effective to implement in clinical practice than clinical criteria based on family history.
LS screening without any age cutoff is presumed to further increase benefit for LS carriers. US guidelines recommended LS screening of all CRC patients by IHC or MSI analysis as a possible screening strategy. 18 However, it is unclear whether the benefit of universal LS screening will come at acceptable costs. In our population-based cohort, the prevalence of LS decreased with increasing age of CRC diagnosis. Recently, universal tumor testing for LS was not found to be cost-effective by a model constructed by Barzi et al. 22 Interestingly, the combination with predictive models was found to be cost-effective, but only in the case of available family history, which is known to be an important clinical challenge. In line with these findings, a German research group also concluded that the most cost-effective strategy involved family-history assessment. 25 A recent international validation study confirmed the validity and potential clinical usefulness of prediction models to direct testing. 37 Strengths of this study are the use of real-life data for index patients and their relatives, inclusion of MLH1 hypermethylation analysis in the diagnostic workup, our detailed analysis of diagnostic costs, and inclusion of gynecological surveillance. To our knowledge, this study is the first cost analysis for LS screening using cost data and family data derived directly from a prospective population-based cohort of CRC patients. In contrast to studies that rely fully on assumptions in cost-effectiveness models, we aimed to stay close to prospectively collected data. Furthermore, minimal cost savings by CRC prevention were used in the calculations. In practice, cost savings from LS screening are likely to be much higher.
This study also has several limitations. First, we did not correct LYG for quality of life. As posed by some, being identified as an LS carrier might not have an impact on quality of life, and it has been suggested that it is not necessary to include quality of life in cost-effectiveness analyses of lifesaving strategies. 38, 39 However, two previous cost-effectiveness analyses of LS screening did find an impact on the ICER by including quality of life. 17, 40 Second, costs and benefit from surveillance for extracolonic cancers other than gynecological cancers were not included in our analyses because these are not generally recommended and the actual benefit of such surveillance is unclear. We also did not include costs of prophylactic colectomy or aspirin chemoprevention. Chemoprevention with aspirin in LS carriers has not yet been implemented because results of the CAPP3 study are pending. 41 Third, we did not perform a full probabilistic sensitivity analysis. Furthermore, in this study we did not evaluate cost-effectiveness of MSI analysis and IHC alone. In previous studies, LS screening by IHC alone was found to be more cost-effective than LS screening by MSI analysis alone or MSI analysis and IHC combined. 16, 17 Finally, in this study we did not include the use of prediction models for LS detection because detailed family history was not available from all patients. MMRpro, MMRpredict, and PREMM 1, 2, 6 have been proposed as prescreening tools for LS. [42] [43] [44] It has been suggested that a combined strategy using IHC and prediction models among CRC patients <70 years of age improves the cost-effectiveness of LS detection. 22, 45 Prediction models may exclude CRC patients with a minimal risk of having LS from molecular diagnostics. Further research should therefore focus on validation of prediction models in population-based cohorts and evaluate the combination with molecular testing for LS.
In conclusion, routine screening for LS in CRC patients up to 70 years of age is a cost-effective strategy according to currently accepted standards, with important clinical benefits for LS carriers among CRC patients and their relatives. Our findings support the recent recommendation for LS screening by analysis of MSI or IHC and MLH1 hypermethylation in all CRC patients ≤70 years of age. 18, 19 
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